Cellular therapies and biotherapies are growing areas of medicine that are transforming patient care. AABB works with the cellular therapies community to drive policies that ensure patient access, advance research, increase the supply and safety biological products, and expand coverage for these transformative therapies.
FDA Seeks Comment on BPD, HCT/P Deviation Reporting
February 25, 2026
FDA Issues Draft Guidance Establishing Framework for Individualized Gene Therapies
February 25, 2026
Japanese Regulatory Panel Recommends Advancing World’s First iPSC-Based Therapies
February 24, 2026